Table 2.
|
GFRα1 expression (n (%)) |
GFRα3 expression (n (%)) |
SDC3 expression (n (%)) |
||||
---|---|---|---|---|---|---|---|
Parameter | n | mRNA | P | mRNA | P | mRNA | P |
Age (years) | |||||||
≤ 35 |
16 |
14 (87.5) |
0.005 |
11 (68.8) |
0.043 |
8 (50.0) |
0.399 |
35-55 |
92 |
45 (48.9) |
|
40 (43.5) |
|
33 (35.9) |
|
> 55 |
51 |
21 (41.2) |
|
17 (33.3) |
|
16 (31.4) |
|
Tumor size (cm) | |||||||
≤ 2 |
13 |
6(46.2) |
0.62 |
4 (30.8) |
0.406 |
7 (53.8) |
0.364 |
2 ~ 5 |
115 |
56 (48.7) |
|
48 (417) |
|
39 (33.9) |
|
> 5 |
31 |
18 (58.1) |
|
16 (51.6) |
|
11 (35.5) |
|
Histologic type | |||||||
Ductal |
150 |
78(52.0) |
0.142 |
67(44.7) |
0.127 |
54(36.0) |
0.333 |
Lobular |
6 |
2(33.3) |
|
1(16.7) |
|
1(16.7) |
|
Mucinous |
3 |
0(0) |
|
0(0) |
|
2(66.7) |
|
Lymph node metastasis | |||||||
0 |
55 |
20 (36.4) |
0.013 |
19 (34.5) |
0.235 |
23 (41.8) |
0.481 |
1 ~ 3 |
55 |
28 (50.9) |
|
24(43.6) |
|
17 (30.9) |
|
>3 |
49 |
32 (65.3) |
|
25 (51.0) |
|
17 (34.7) |
|
Grade | |||||||
I |
13 |
8 (61.5) |
0.436 |
6 (46.2) |
0.678 |
7 (53.8) |
0.124 |
II |
102 |
53 (52.0) |
|
41 (40.2) |
|
31 (30.4) |
|
III |
44 |
19 (43.2) |
|
21 (47.7) |
|
19 (43.2) |
|
Stage | |||||||
I-II |
85 |
32 (37.6) |
0.001 |
32 (37.6) |
0.162 |
31 (36.5) |
0.861 |
III-IV |
74 |
48 (64.9) |
|
36(48.6) |
|
26 (35.1) |
|
ER status ^ | |||||||
- |
94 |
49 (52.1) |
0.582 |
37 (39.4) |
0.297 |
31 (33.0) |
0.364 |
+ |
65 |
31 (47.7) |
|
31 (47.7) |
|
26 (40.0) |
|
PR status ^^ | |||||||
- |
90 |
44 (48.9) |
0.681 |
36 (40.0) |
0.421 |
27 (30.0) |
0.079 |
+ |
69 |
36 (52.2) |
|
32 (46.4) |
|
30 (43.5) |
|
HER-2 * | |||||||
- |
121 |
53 (43.8) |
0.003 |
47 (38.8) |
0.074 |
44 (36.4) |
0.809 |
+ | 38 | 27 (71.1) | 21 (55.3) | 13 (34.2) |
^ ER positive required at least 10% staining nuclei.
^^ PR positive required at least 10% staining nuclei.
HER-2 positive were 3+ or 2+ and FISH confirmed.
Values in bold are significant (P < 0.05).